INDIANAPOLIS, July 1, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its U.S. Diagnostics unit was ranked number one in overall service performance by clinical laboratories in the 2013 ServiceTrak Clinical Report. The report was issued by IMV Ltd, an independent firm that produces an annual series of proprietary reports derived from extensive phone surveys of clinical laboratory professionals to determine their level of satisfaction with the service they receive from the manufacturers of their clinical diagnostic equipment.
In the report, customers rated the Roche Support Network first in overall service performance in both chemistry and immunoassay testing categories. Report results are based on questions related to 46 attributes assessing the level of satisfaction among laboratory professionals with a manufacturer, its system(s) and its service performance.
"We are honored to be recognized by laboratories for our service performance," said Reg Stump, vice president, Roche Support Network. "Service plays a key role in helping labs stay up and running so they can deliver reliable test results to physicians and patients. This recognition indicates to us that our efforts to help labs maximize their productivity are having a positive impact."
IMV (www.imvinfo.com) is a market research consulting firm founded in 1977 specializing in clinical diagnostics, diagnostic imaging, patient monitoring and other advanced healthcare technology markets. IMV's marketing and sales consulting services, in combination with our census databases of U.S. in-vitro diagnostic testing, diagnostic imaging sites and radiation oncology facilities, provide clients with valuable market information in strategic planning, sales initiatives, customer satisfaction and product development.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com or www.roche-diagnostics.us.
All trademarks used or mentioned in this release are protected by law.
For further information, please contact:
Director, Corporate Communications
Roche Diagnostics Corporation
SOURCE Roche Diagnostics